No menu items!
12.3 C
Sunday, May 9, 2021
No menu items!

Gemini Pharmaceuticals Nigeria Limited Recruitment Portal

Must read

Gemini Pharmaceuticals Nigeria Limited is one of the foremost pharmaceutical companies in the country. It offers a diverse range of pharmaceutical products to a broad range of customers across the country. Most essentially, through this article, we bring you to the knowledge of Gemini Pharmaceuticals Nigeria Limited Recruitment, how to apply, and so on.

Gemini Pharmaceuticals Nigeria Limited Recruitment

Gemini Pharmaceuticals Nigeria Limited, also called GPNL, is a pharmaceutical company incorporated in 1972 under the Companies Act, 1968 of the Federal Republic of Nigeria. Meanwhile, the company was founded by Bayer A.G. Leverkusen, and Dr. M. B. Unuane with the sole aim to manufacture and market Bayer AG’s Pharmaceutical Specialties in Nigeria. In the beginning, 40% of its shares belonged to Nigerians whilst 60% was owned by Bayer AG Leverkusen, West Germany.

Secondly, in 1974, there was a Joint Venture agreement between Dr. T. A. Odutola, Dr. M. B. Unuane, and Bayer AG, Leverkusen. That is, the agreement prompted the changing of the company’s name to Bayer Pharmaceuticals Nigeria Limited. In order to ensure a successful expansion, the company bought 12 acres of land at Apapa/Oshodi Express Amuwo- Odofin, Lagos. In essence, the land was specifically set aside for the construction of a Pharmaceutical Manufacturing Company. The state-of-the-art factory was launched in 1982. Also, business operations began the same year.

Moreover, in the late ’80s, Bayer A.G. intentionally disengaged from its operations in the third world countries so as to enable indigenes to own and manage their subsidiary companies. Also, the disengagement was prompted by the company’s global policy which made a provision for that.

Also, following the disengagement, the share of Dr.T. A. Odutola and Bayer AG was purchased by DR. M. B. UNUANE. Meanwhile, the company was officially handed to DR. M. B. UNUANE on 30th June 1993. And the exercise instantly leads to the changing of the company’s name to its current name, “Gemini Pharmaceutical Nigeria Limited”. The new owner of the company had a Licence and Franchise Agreement to continue to produce Bayer AG Pharmaceutical Specialties in Nigeria until 2002.

Points To Note About Gemini Pharmaceuticals Recruitment

Moreover, at GPNL, we value trust, diversity, integrity, and ingenuity as a company and in our staff. This dedication showcases our policy to afford an equal chance to qualified persons. In our recruitment, we do not discriminate against gender, religion, age, or disability. Meanwhile, this is more than just being obedient to laws, it is a dedication. It is the recognition of individual peculiarity and the value of a diverse workforce.

Recruitment Requirements

The requirements to apply for the recruitment are as follows:

  1. B.Sc/HND in any relevant discipline obtained from a recognized institution.
  2. OND/NCE in any relevant discipline obtained from a recognized institution.
  3. General Certificate of Education (Advanced Level) in two (2) subjects obtained at one sitting or three (3) subjects obtained at two sittings
  4. Candidate must have a minimum of 5 credits in SSCE/WASSCE (including Mathematics and English Language) at a sitting, or 6 credits at not more than 2 sittings.
  5. Any other qualifications that are equivalent to the ones listed above
  1. Good interpersonal skill and ability to work in a team
  2. Excellent written and oral communicative skills.
  3. Must be computer literate.
  4. NYSC discharge/exemption certificate.

However, we passionately wish to inform you that Gemini Pharmaceuticals Nigeria Limited Recruitment has not begun. Definitely, the recruitment process shall begin in due season. Anytime it starts, we shall bring you updates on that.

Most importantly, for the latest updates on the recruitment, visit this website often. Or you can reach out to the Recruitment Portal through this whiteniche link, for updates.

All rights reserved.
This material and other digital content on this website may not be reproduced, published, broadcast, rewritten, or redistributed in whole or in part without prior express written permission from

- Advertisement -
- Advertisement -

Latest article